Principal and Sub-investigators:

Jasjit Walia, MD, FACC, MBA
Dr. Walia is a highly recommended invasive cardiologist who is board certified in cardiovascular diseases and Internal Medicine.

Dr. Walia is actively involved in research and training of medical students, residents, fellows and other physicians. His patients appreciate his considerate bedside manners and the human touch that he brings to their overall care. He believes in communicating with patients and their family members on a personal level, which has earned him the loyalty of his patients. He is fluent in English, Indian languages and speaks Spanish as well. Below is a brief description of the research that Dr. Walia conducted:

• ARRIVE Study (co-Investigator) Aspirin to Reduce Risk of Initial Vascular Events, a phase IIIb, randomized, multicenter, double-blind, placebo-controlled, parallel-group trial in patients at moderate risk of CHD events. To evaluate the clinical effects of a 100mg/day enteric coated acetylsalicylic acid versus placebo in the reduction of CVD events in patients with moderate risk of major CHD events.
• Dorado study (Co-Investigator), Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension. Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or more Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo
• Aortic rupture: comparison of three imaging modalities Journal Emergency Radiology Issue Volume 13, Number 1
• The Journal of Cardiac Electrophysiology for publication has accepted Cardionet Trial. The Diagnosis of Cardiac Arrhythmias: A Prospective Multi-Center Randomized Study Comparing Mobile Cardiac Outpatient Telemetry versus Standard Loop Event Monitoring.
• Investigator for -A-HeFT (African-American Heart Failure Trial)- Placebo-Controlled Trial of BiDil Added to Standard Therapy in African-American Patients with Heart Failure.
• ACT Study the purpose of this registry to produce a prospective, outcome-oriented registry of all patients implanted with an SJM ICD. The secondary aim of the registry is to evaluate the programming and application of advanced features on ICD therapy in patients with SJM ICD's
• ULTRA- The primary objective of the Ultra study is to demonstrate a difference in average ventricular voltage output over time for patients randomized to Automatic Capture ON versus patients randomized to Automatic Capture OFF. The primary analysis for this objective will be based on the difference between the groups in the average ventricular voltage output over the course of follow-up.
• OMNI- The Medtronic OMNI Study is a post-market observational study conducted in the United States (US). The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator (ICD)
• MEDTRONIC P3- The objective of the P3 study is to characterize the relationship between subject clinical profiles at implant. Also to characterize clinical outcome and clinical management practice patterns

Preet Randhawa, MD, FACC
Dr. Preet Randhawa is an Interventional Cardiologist and is board certified in Internal Medicine, Cardiology and Interventional Cardiology and He is also a Clinical Assistant Professor-UMDNJ-New Jersey Med School. Director of Interventional Cardiology and co-director Cath Lab, UMDNJ.

He finished his cardiology training at Wayne State University, Detroit, and then served as a faculty Member at the world-class Henry Ford Hospital, where he also completed his angioplasty training.

Dr. Preet Randhawa is one of the founding partners of NJHeart. He is also the founder of the emergency angioplasty program at Trinitas Hospital. He performs 800 to 1,000 diagnostic and interventional procedures each year. He has been in practice in New Jersey since 2002. In addition to cardiac procedures he sees patients in the office and performs hospital consultations. His focus is on preventive cardiology and he works along with his patients to modify cardiac risk factors, such as quitting smoking and increasing exercise capacity. This approach, along with early detection of cardiac disease, helps in reducing the risk of an adverse outcome in the future. Below is a brief description of the research that Dr. Randhawa conducted:

• ARRIVE Study (co-Investigator) Aspirin to Reduce Risk of Initial Vascular Events, a phase IIIb, randomized, multicenter, double-blind, placebo-controlled, parallel-group trial in patients at moderate risk of CHD events. To evaluate the clinical effects of a 100mg/day enteric coated acetylsalicylic acid versus placebo in the reduction of CVD events in patients with moderate risk of major CHD events.
• Dorado study (Co-Investigator), Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension. Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or more Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo
• Aortic rupture: comparison of threeimaging modalities Journal Emergency Radiology Issue Volume 13, Number 1.
• Co-Investigator—Atlantic C-PORT Trial for elective angioplasty-Trinitas Hospital
• Cardionet trial Diagnostic utility of Cardio-Net monitor
• Medtronic P3- to characterize the relationship between subject clinical profiles at implant. Also to characterize clinical outcome and clinical management practice patterns.
• ACT(Advance in ICD Therapy) - the purpose of this registry to produce a prospective, outcome-oriented registry of all patients implanted with an SJM ICD. The secondary aim of the registry is to evaluate the programming and application of advanced features therapy in patients with SJM ICD
• ULTRA-To demonstrates a difference in average ventricular voltage output over time for patients randomized to Automatic Capture on versus patients randomized to Automatic Capture Off.
• Omni-Post market observation study to characterize therapy and diagnostic utilization to describe ICD therapy for life threatening arrhythmias in primary and secondary prevention study participants.
• A-Heft study- to look at the benefit of BiDil therapy in African American patients with class III to IV CHF
• SPLASH Trial, Co-Investigator in the Sonotherapy Prevention of Late Arterial In-Stent hyperplasia
• Participated in a randomized open-label outpatient study to evaluate active Lipid Clinic management versus conventional lipid management in patients with angiographically detected coronary artery disease in the cardiac catheterization laboratory. (ALMICAD) A retrospective chart review to determine the positive and negative predictive values of all non-invasive modalities to differentiate ischemic from non-ischemic cardiomyopathy, using cardiac catheterization as the diagnostic gold standard.
• Wayne State University/ Detroit Medical Center Detroit, MI. A randomized, double blind, placebo-controlled study of the effects of infusion of adenosine in acute anterior MI undergoing PTCA/stent on Coronary Flow Reserve (CFR) and micro vascular function as measured by PET scan. The effects of infusion of adenosine in acute anterior MI undergoing PTCA/stent on Coronary Flow Reserve (CFR) and micro vascular function as measured by PET scan.
• Solution (SOS) on inflammation induced by ultraviolet light on a mouse ear model by measuring myeloperoxidase levels. Measured ischemia-reperfusion injury in rabbit rectus femoris muscle model using myeloperoxidase and Evan blue.
• Studied Mechanism of acute blood pressure elevation during repetitive hypocapnic and eucapnic hypoxia in rats. Conducted a double blind, placebo-controlled study of the efficacy and safety of three doses of CP-0127 (a bradykinin antagonist) and placebo in patients with presumed sepsis and systemic inflammatory response syndrome (SIRS).

ABSTRACT

Bao G, Preet M. Randhawa, and Fletcher EC. Mechanism of acute blood pressure elevation during episodic hypercapnic hypoxia in rats simulating sleep apnea. Clin Res 1994, 42:382A

Bao G, Preet M. Randhawa, and Fletcher EC. Mechanism of blood pressure elevation and bradycardia during intermittent hypoxia in borderline hypertensive rats. ATS International Conference. Seattle, WA, 1995

Bao G, Preet M. Randhawa, and Fletcher EC. Mechanism of blood pressure, elevation and bradycardia during intermittent hypoxia in borderline hypertensive rats. Am J of Resp and Critical Care Med April 1995, Vol 151(Abstracts)

JOURNALS

1. Bao G, Preet M. Randhawa, and Fletcher EC. Mechanism of acute blood pressure elevation during repetitive hypocapnic and eucapnic hypoxia in rats. Journal of Applied physiology 82(4): 1071-8,1997 Apr.
http://jap.physiology.org/cgi/content/full/82/4/1071

2. Management of a Left Ventricular Aneurysm in an Adult" by Doctors Sorin V. Pusca, Barry C. Esrig, Preet M. Randhawa, Dusan Knezevic, and Muhamed Saric, University of Medicine and Dentistry of New Jersey, Newark, NJ. View CTSNet
http://www.ctsnet.org/sections/clinicalresources/clinicalcases/article-4.html

3. Aortic rupture: comparison of three imaging modalities Monica Sanchez-Ross, Ather Anis, Jasjit Walia, Preet Randhawa, Barry C. Esrig, Michael C. Banker, Corey Eber, Pierre Maldjian, Marc Klapholz and Saric, Journal Emergency Radiology Issue Volume 13, Number 1 / September, 2006
http://WWW.SPRINGERLINK.COM/CONTENT/HL6X02JH85P18203/

BOOK CHAPTER
Pharmacological Interventions.
Preet Randhawa. WD Weaver.
Fibrinolytic Therapy in Clinical Practice.
Martin Dunitz Ltd.

Sabato J. Lombardo, MD
Dr.Lombardo, a lifelong New Jersey resident, has practiced Internal Medicine and Cardiology in Union County for more than 20 years.

A graduate of Rutgers Medical School (now known as UMDNJ/Robert Wood Johnson Medical School), he is board certified by the American Board of Internal Medicine and by the American College of Cardiology.

Zahir Rahman, MD
Dr. Rahman is board certified in cardiovascular diseases and Internal Medicine.

A graduate of University of California, San Diego, and of Finch University of Health Sciences, Chicago, Dr. Rahman has practiced in New York and New Jersey since 1999.

Known for his considerate bedside manner and thorough follow-up care of his patients, he is a highly sought after physician.

Hyeun Park, MD
Dr. Hyeun (Tom) Park is a non-invasive Cardiologist and is board certified in Nuclear Cardiology, Echocardiography and Internal Medicine and Cardiology.

Dr. Park completed his cardiology training at Westchester Medical Center in Valhalla, NY. During his training, he has written several publications in peer-reviewed cardiology journals.

Dr. Park keeps up-to-date on the latest scientific and medical literature. He believes in practicing evidence-based cardiology. Dr. Park is well liked by his patients, colleagues, other medical staff, and hospital employees. He has good bedside manner and is known by his patients to be attentive, honest, and compassionate. Below is a brief description of the research that Dr. Park conducted:

• Research on the impact of age and gender with echocardiographic indications of left ventricular diastolic dysfunction.
• Evaluation of left ventricular diastolic dysfunction by comparing septal versus lateral mitral annulus tissue Doppler measurements
• Relation of ankle-brachial index to prevalence of atherosclerotic risk factors, of coronary artery disease, of aortic valve calcium, and of mitral annular calcium
• Research in cardiac electrophysiology regarding the utility of continuation studies after successful AVRT and AVRNRT ablations.

D. Scott Alenick, M.D. is a board-certified pediatric cardiologist. He treats all aspects of pediatric cardiac care, from fetal echocardiography to adults with congenital heart conditions.

Dr. Alenick and his staff are committed to providing our patients and families, with the highest quality healthcare in a professional and caring manner.

Dr. Alenick was recognized as the Physician Of The Year in 1996 by Hippocrates magazine.

Rakesh Sharma, MD, FCCP
Nigam Avinash

Linda Exume, MA
Research Coordinator

Vikram Parikh
Research coordinator 1yr experience in clinical trials, foreign medical graduate, and ECFMG certified.

Mahesh Kumar
Research Coordinator foreign medical graduate

We have a large database, referring Doctors, and also our physicians are affiliated with all of the area hospitals.

We have 5 offices throughout NJ; our main office for the research department is in Linden, which have a dedicated area for site managers and monitors with computer and high speed Internet, and telephones and labs for collecting laboratory samples. In addition we have one research company opening in New Delhi, India in September, which will be involved in conducting all area of clinical researches including device studies.

NJ Heart
Elizabeth Office
240 Williamson St.
Suite #402
Elizabeth, NJ 07202
Toll Free: (1-877-heart-35)
Phone: (908)354-8900
Fax: (908)354-0007

NJ Heart
Linden Office
520 N. Wood Ave.
Linden, NJ 07036
Toll Free: (1-877-heart-35)
Phone: (908)587-9300
Fax: (908)587-1901

NJHeart/Medsleep
515 N. Wood Ave Suite 201
Linden, NJ 07036
Phone: (908)486.1387
Fax: (908)486.1333

NJ Heart
Union Office
1308 Morris Ave.
Union, NJ 07083
Toll Free: (1-877-heart-35)
Phone: (908)687-8686
Fax: (908)687-9694

NJ Heart
Newark Office
635 Market Street
Newark, NJ 07105
Toll Free: (1-877-heart-35)
Phone: (973)344-5454

For more information, please contact:

Linda Exume
Research Coordinator
NJ Heart Research
520 N Wood Ave
Linden, NJ 07036 USA
Phone: 908-486-1388/ 908-587-9300
Fax: 908-486-1333/ 908-587-1901
E-mail:

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

Last updated on February 19, 2008

PAC>